Feature | September 23, 2013

National Registry Report Shows Increase in Radial Stenting, Other CV Trends

September 23, 2013 — Cardiologists are increasingly accessing coronary arteries by way of the wrist rather than the groin to insert life-saving stents into patients with blocked arteries, according to the first broad report of the American College of Cardiology’s clinical data registries published online in the Journal of the American College of Cardiology.

The report, “Cardiovascular Care Facts: A Report from the National Cardiovascular Data Registry ? 2011,” includes data about stents from the CathPCI Registry, the ACC’s national database of hospital records on stenting and angioplasty, as well a wide range of data from the other four ACC National Cardiovascular Data Registries for which comprehensive data from 2011 are available.

The report showed stenting (percutaneous coronary intervention or PCI) performed at the radial access site (the wrist) increased from 2.9 percent of cases in 2009 to 10.9 percent of cases in 2011, while stenting performed at the femoral access site (the groin) decreased from 96.5 percent to 88.8 percent during the same time period. While this approach is new and still being studied, research has shown that radial access can reduce the risk of complications, discomfort and recovery times in some patients. The report suggests that clinicians who perform PCI are becoming more comfortable with this approach and it is becoming more commonly used.

"The data in this report demonstrate the value of national registries in providing an unprecedented and broad perspective on the care and outcomes of patients with cardiovascular disease,” said Frederick Masoudi, M.D., MSP, senior medical officer of the NCDR. “These registries are key tools in understanding and improving care for cardiovascular patients across the United States."

Other top findings from the report outline several successes in heart disease care as well as opportunities for further improving a patient’s treatment and follow-up care experience.

There have been continued improvements in meeting guideline-recommended door-to-balloon (D2B) times of 90 minutes or less for patients with ST-segment elevation myocardial infarction. In the ACTION-GWTG Registry alone, the proportion of patients with D2B times of 90 minutes or less for non-transfer patients increased from 81 percent in 2008 to 94.2 percent in 2011, while among patients who were transferred for percutaneous coronary intervention (PCI) this proportion increased from 18 percent in 2008 to 30.4 percent in 2011.

Findings from the CathPCI Registry show providers are consistently prescribing optimal medical therapy, including aspirin, thienopyridine/P2Y12 inhibitor, lipid lowering agents and beta-blockers, at discharge for PCI patients. Prescription of aspirin and thienopyridine at discharge have remained relatively steady between 96 percent and 98 percent between 2009 and 2011, while prescriptions of lipid lowering agents and beta blockers have increased. Prescription of lipid lowering agents rose from 89.7 percent in 2009 to 92.5 percent in 2011. Beta blocker prescriptions have increased from 83.1 percent to 86.3 percent.

In the PINNACLE Registry, data show there continues to be an opportunity for increased education for patients and clinicians about optimal anticoagulation strategies for stroke prevention in atrial fibrillation, as 57.2 percent of eligible patients with atrial fibrillation were prescribed anticoagulation therapy.

The ICD Registry identifies an opportunity for the use of medical therapy for patients with prior myocardial infarction or left ventricular systolic dysfunction; nearly 25 percent of ICD patients did not receive optimal medical therapy with ACE inhibitors and/or beta blockers at discharge.

PINNACLE Registry data overwhelmingly shows providers regularly recording patient blood pressures (95.1 percent), only a minority (34.5 percent) of providers are taking things a step further and implementing hypertension care plans.

According to CathPCI Registry data, opportunities exist to improve not only adherence to appropriate use criteria in patients without acute coronary syndrome (ACS) but potentially clarify areas of uncertainty. While a little more than half of patients without ACS (52.8 percent) were evaluated appropriately for PCI procedures, 37.3 percent fell into the uncertain category, while nearly 10 percent were inappropriate. In contrast, patients with ACS were appropriately evaluated for PCI procedures 99.1 percent of the time.

For more information: cardiosource.org/ACC

Related Content

Stereotaxis, Philips, collaboration, Niobe ES remote magnetic navigation system, Allura Xper FD10 cardiovascular X-ray

Niobe ES image courtesy of Stereotaxis Inc.

Technology | Cath Lab| February 04, 2016
February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Coopera
medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Medtronic, CE Mark, Resolute Onyx DES, drug-eluting stent, expanded sizes and indications
News | Stents Drug Eluting| February 02, 2016
Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES,...
TOBA-BTK study, six-month results, LINC 2016, Tack Endovascular System
News | Peripheral Arterial Disease (PAD)| January 29, 2016
Intact Vascular Inc. announced that positive six-month results from its Tack Optimized Balloon Angioplasty – Below-the-...
Toshiba, CT-angiography, hybrid OR

Toshiba recently introduced a new line of combined CT and angiography systems, allowing true CT imaging on demand in the interventional lab.

Feature | Angiography| January 27, 2016 | Dave Fornell
All of the major vendors in the United States introduced new systems and technologies in the past few years to reduce...
Technology | Ultrasound Intra-cardiac Echo (ICE)| January 26, 2016
Conavi Medical Inc. (formerly Colibri Technologies Inc.) has received U.S. Food and Drug Administration (FDA) 510(k)...
medical device excise tax, two-year suspension, U.S. market, GlobalData analyst
News | Business| January 25, 2016
The suspension of the medical device excise tax will have positive consequences for the U.S. medical device market over...
Abbott, Absorb, BVS, FDA review, FDA panel

The Abbott Absorb BVS.

News | Cath Lab| January 20, 2016 | Dave Fornell
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel is set to review data and offer...
Vivasure Medical, PerQSeal, vascular closure device, CE Mark
News | Vascular Closure Devices| January 18, 2016
Vivasure Medical announced Conformité Européenne (CE) Mark approval of the world’s first fully bioabsorbable...
Medtronic, CE Mark, IN.PACT Admiral DEB, arteriovenous AV access, hemodialysis, end-stage renal disease patients
News | Drug-Eluting Balloons| January 18, 2016
Medtronic plc announced that the IN.PACT Admiral drug eluting balloon (DEB) has received CE (Conformité Européene) Mark...
Overlay Init